The 'Leucocyte Coping Capacity' test for identifying radiorecurrent prostate cancer: a pilot study.
The 'Leucocyte Coping Capacity' test for identifying radiorecurrent prostate cancer: a pilot study.
复制标题
用于识别放射性复发性前列腺癌的“白细胞应对能力”测试：一项试点研究。
DOI：
10.1111/bju.16043
复制
发表时间：
2023
影响因子：
4.5
通讯作者：
Shah,TaimurT
中科院分区：
文献类型：
--
作者：
Light,Alexander;Li,Xiaomeng;Otieno,Marjorie;Ahmed,HashimU;Shah,TaimurT
炎症是癌症的标志，有证据表明中性粒细胞有助于许多癌症的发生、发展和进展[1]。中性粒细胞与淋巴细胞比率是中性粒细胞数量的标志物，可反映前列腺癌的预后[2];中性粒细胞功能的标志物可能具有类似的作用[2]。这可能是重要的放射治疗后。每年有12，000名英国男性接受外束放射治疗（EBRT），但大约20%的人在5年内出现生化复发[3，4]。通常情况下，PSA升高会触发重新分期，通常使用高于最低值≥ 2.0 ng/mL的Phoenix阈值[5]。一个简单，准确的测试与PSA可以澄清可疑的复发在一个给定的时间点，可以促进早期restaged.We进行了一项试点研究，为此目的，评估新的白细胞免疫测试™（LIT; Seroxo有限公司，英国）。该即时检测评估白细胞产生活性氧的能力。我们假设较高的LIT评分，反映了中性粒细胞活性的增加，可能与放射复发的存在和程度相对应。参与者是FORECAST前瞻性配对队列研究（NCT 01883128）的一部分[6]。2014-2018年期间，从6个英国中心入组了181例EBRT或近距离放射治疗伴/不伴（新）辅助雄激素剥夺治疗（ADT）后生化失败的患者。生化失败由转诊临床医生定义;我们的方案没有要求
Inflammation is a cancer hallmark, with evidence suggesting neutrophils contribute to the initiation, development, and progression of many cancers [1]. Neutrophil-to-lymphocyte ratio, a marker of neutrophil number, reflects prognosis in prostate cancer [2]; markers of neutrophil function could have a comparable role [2]. This may be important postradiotherapy.> 12,000 UK men undergo external beam radiotherapy (EBRT) yearly, but approximately 20% develop biochemical recurrence within 5 years [3, 4]. Typically, PSA rises trigger re-staging, with the Phoenix threshold of≥ 2.0 ng/mL above-nadir often used [5]. A simple, accurate test alongside PSA may clarify suspicion of recurrence at a given timepoint and could facilitate earlier re-staging.We performed a pilot study for this purpose, evaluating the novel Leukocyte ImmunoTest™(LIT; Seroxo Ltd, UK). This point-of-care assay assesses leucocyte ability to produce reactive oxygen species. We hypothesised higher LIT scores, reflecting increased neutrophil activity, may correspond with the presence and degree of radiorecurrence. Participants were part of the FORECAST prospective paired-cohort study (NCT01883128)[6]. Between 2014–2018, 181 patients were enrolled from 6 UK centres with biochemical failure after EBRT or brachytherapy with/without (neo) adjuvant androgen deprivation therapy (ADT). Biochemical failure was defined by the referring clinician; our protocol did not mandate